Literature DB >> 10648441

Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study.

M T Hu1, S D Taylor-Robinson, K R Chaudhuri, J D Bell, C Labbé, V J Cunningham, M J Koepp, A Hammers, R G Morris, N Turjanski, D J Brooks.   

Abstract

Regional cerebral phosphorus-31 magnetic resonance spectroscopy ((31)P-MRS) was performed in 10 non- demented Parkinson's disease patients and nine age-matched control subjects. Five of the patients undergoing (31)P-MRS and four additional Parkinson's disease patients had cerebral 2-[(18)F]fluoro-2-deoxy-D-glucose PET ((18)FDG-PET), the results of which were compared with those of eight age-matched control subjects. All Parkinson's disease patients underwent neuropsychological testing including performance and verbal subtests of the Wechsler Adult Intelligence Scale-Revised, Boston Naming Test, Controlled Oral Word Association test (FAS Test) and California Learning Test to exclude clinical dementia. (31)P MR spectra from right and left temporo-parietal cortex, occipital cortex and a central voxel incorporating basal ganglia and brainstem were obtained. (31)P MR peak area ratios of signals from phosphomonoesters (PMEs), inorganic phosphate (P(i)), phosphodiesters (PDEs), alpha-ATP, gamma-ATP and phosphocreatine (PCr) relative to beta-ATP were measured. Relative percentage peak areas of PMEs, P(i), PDEs, PCr, and alpha-, beta- and gamma-ATP signals were also measured with respect to the total (31)P-MRS signal. Significant bilateral increases in the P(i)/beta-ATP ratio were found in temporoparietal cortex (P = 0.002 right and P = 0.014 left cortex) for the non-demented Parkinson's disease patients compared with controls. In the right temporoparietal cortex, there was also a significant increase in the mean relative percentage P(i) (P = 0.001). (18)FDG-PET revealed absolute bilateral reductions in glucose metabolism after partial volume effect correction in posterior parietal and temporal cortical grey matter (P < 0.01 and P < 0.05, respectively) for the Parkinson's disease group, using both volume of interest analysis and statistical parametric mapping. There were significant correlations between right temporoparietal P(i)/beta-ATP ratios and estimated reductions in performance IQ (r = 0.96, P < 0.001). Left temporoparietal P(i)/beta-ATP ratios correlated with full scale IQ and verbal IQ (r = -0.82, P = 0.006, r = -0.86, P = 0.003, respectively). In summary, temporoparietal cortical hypometabolism was seen in non-demented Parkinson's disease patients with both (31)P-MRS and (18)FDG-PET, suggesting that both glycolytic and oxidative pathways are impaired. This dysfunction may reflect either the presence of primary cortical pathology or deafferentation of striato-cortical projections. (31)P-MRS and (18)FDG-PET may both provide useful predictors of future cognitive impairment in a subset of Parkinson's disease patients who go on to develop dementia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648441     DOI: 10.1093/brain/123.2.340

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  55 in total

1.  Implementation and application of a brain template for multiple volumes of interest.

Authors:  Alexander Hammers; Matthias J Koepp; Samantha L Free; Matthew Brett; Mark P Richardson; Claire Labbé; Vincent J Cunningham; David J Brooks; John Duncan
Journal:  Hum Brain Mapp       Date:  2002-03       Impact factor: 5.038

2.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

3.  Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson's disease.

Authors:  Chul Hyoung Lyoo; Young Hoon Ryu; Myung Sik Lee
Journal:  J Neurol       Date:  2011-04-22       Impact factor: 4.849

Review 4.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 5.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

6.  A nested phosphorus and proton coil array for brain magnetic resonance imaging and spectroscopy.

Authors:  Ryan Brown; Karthik Lakshmanan; Guillaume Madelin; Prodromos Parasoglou
Journal:  Neuroimage       Date:  2015-09-13       Impact factor: 6.556

7.  Regional gray matter atrophy in patients with Parkinson disease and freezing of gait.

Authors:  A Tessitore; M Amboni; G Cirillo; D Corbo; M Picillo; A Russo; C Vitale; G Santangelo; R Erro; M Cirillo; F Esposito; P Barone; G Tedeschi
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

Review 8.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

9.  Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing.

Authors:  Y Abe; T Kachi; T Kato; Y Arahata; T Yamada; Y Washimi; K Iwai; K Ito; N Yanagisawa; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

10.  Whole-brain proton MR spectroscopic imaging in Parkinson's disease.

Authors:  Bonnie E Levin; Heather L Katzen; Andrew Maudsley; Judith Post; Connie Myerson; Varan Govind; Fatta Nahab; Blake Scanlon; Aaron Mittel
Journal:  J Neuroimaging       Date:  2012-12-10       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.